ClinicalTrials.gg
RecruitingNCT07351149POAKIDSUpdated Sep 29, 2026

Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery

An observational study in Acute Kidney Injury, sponsored by Uppsala University. Recruiting at 16 sites in 10 countries. Open to participants aged 0 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Uppsala University · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Sep 29, 2026First sites in Canada, Croatia and NetherlandsSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
0 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Acute Kidney Injury by Uppsala University — 5 open to participants now, 6 under way, none of them phase 3. Acute Kidney Injury · Uppsala University.

Started
2026
the only one that year
Observational
9 of 11
5 open now
Registered
11th of 11
by date

Among the 11 studies in Acute Kidney Injury by Uppsala University, this one is the only one that started in 2026, is one of 9 observational ones, and was the 11th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

5 of the 11 studies in Acute Kidney Injury by Uppsala University are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 0 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Acute Kidney Injury by Uppsala University, or all of them as a file.
02

Study summary

This project aims to conduct an international, prospective, multicentre, observational study to determine the incidence of Postoperative Acute Kidney Injury (PO-AKI) in hospitalized children after noncardiac surgery. Urinary biomarkers are intended to be evaluated as predictors of PO-AKI in the same subjects. The study employs modern standardized classifications for AKI to comprehensively address the issue of PO-AKI in children. Describing the incidence and identifying risk factors for PO-AKI will play a crucial role in developing preventive strategies aimed at reducing associated mortality and morbidity. Furthermore, investigating the relationship between urinary biomarkers of renal injury and PO-AKI will provide valuable insights into assessing postoperative renal function in paediatric patients, especially when repeated blood sampling is not feasible.

Read the detailed description

INTRODUCTION Acute Kidney Injury refers to a sudden impairment in renal function, reflected by increased plasma creatinine concentration and/or decreased urine output. Traditionally, only the most severe reduction in renal function with azotemia and anuria has been emphasised as significantly deleterious, but during the last decades evidence suggests that acute, relatively mild or moderate injury to the kidney portend serious clinical consequences. In critical illness, AKI is strongly associated with short-term mortality as well as chronic kidney disease, cardiovascular disease, and premature death, even when kidney function has recovered.

PO-AKI is characterized by a sudden and significant decline in renal function after surgery. In adults, it is established that PO-AKI is common, imposes a heavy burden of illness, is amenable to early detection and potential prevention and infers a high cost per person in management. There is also considerable variability in practice to prevent, diagnose, treat and achieve outcomes of AKI. Detailed knowledge of incidence rates, risk factors, and outcomes of PO-AKI have considerably enhanced our understanding of optimal treatment and prevention strategies.

Compared to the adult population, there remains a paucity of research data pertaining to PO-AKI for noncardiac surgery in children. However, there is a rational presumption that identifying, preventing, and treating a condition like PO-AKI, which carries enduring long-term consequences, would be particularly advantageous in paediatric patients. The known high burden of AKI in children who are critically ill or undergoing cardiac surgery underscore the importance of accurately and prospectively describing incidence and risk factors for paediatric PO-AKI.

Contemporary evidence advocates for the utilization of innovative urinary biomarkers in predicting and managing AKI. Nevertheless, additional studies are imperative to advance scientific and clinical comprehension regarding the optimal methods and timing for their application, not the least in the perioperative setting. The clinical promise of these biomarkers is particularly pronounced in paediatric populations due to the considerable impediment posed by the necessity for frequent blood sampling in diagnosing and staging PO-AKI within this group. Further investigation stands to enhance the understanding and implementation of these biomarkers, offering substantial potential benefits in the management of paediatric PO-AKI. However, data regarding PO-AKI in paediatric patients, especially those undergoing noncardiac surgery, are notably limited.

RESEARCH QUESTIONS

  1. What is the incidence of paediatric PO-AKI in hospitalized children after noncardiac surgery?
  2. Can urinary biomarkers, novel and established, accurately predict paediatric PO-AKI?
  3. What are the risk factors for AKI in children undergoing anaesthesia and surgery?

THE NEED FOR THE RESEARCH In adults, the impact of PO-AKI is extensively documented. Research indicates a notable disparity in the incidence of kidney failure among individuals who experience PO-AKI compared to those who do not. Specifically, at the one-year mark, the occurrence of kidney failure stands at 0.94% in individuals who have encountered PO-AKI, as opposed to a significantly lower rate of 0.05% in those without such a history. This trend persists over a decade, with kidney failure presenting in 0.4% of patients devoid of renal impairment post-surgery, whereas 2.3% of those affected by PO-AKI develop kidney failure within the same period. PO-AKI also further impair an already reduced renal function. While 7.3% of patients with Chronic Kidney Disease (CKD) progress to kidney failure over ten years, this figure elevates to 15.7% for individuals with CKD who have experienced PO-AKI. Even when kidney function fully recovers, individuals with a history of PO-AKI exhibit persistently inferior survival rates over a ten-year period. Additionally, patients who undergo PO-AKI face heightened risks of recurrent AKI episodes and future reliance on renal replacement therapy. Various postoperative complications, such as infections, prolonged mechanical ventilation, tracheostomy, and cardiovascular events, are more prevalent among patients who develop PO-AKI post-surgery compared to those who do not. Furthermore, PO-AKI incurs substantial hospitalization costs and increased utilization of resources. Thus, in adults PO-AKI pose a serious problem.

PAEDIATRIC POSTOPERATIVE ACUTE KIDNEY INJURY Millions of children undergo various surgical procedures globally each year, ranging from routine to complex surgeries. Limited research has focused on paediatric PO-AKI using contemporary criteria for renal dysfunction in noncardiac surgery. The majority of existing studies are retrospective, single-centre investigations reporting widely varied incidence of PO-AKI, ranging from 3.2% to 62.3%. Only one study is from Europe and two are prospective. Importantly, several studies focus solely on neonatal PO-AKI.

Large, well-performed studies in critically ill neonates and children demonstrate an incidence of AKI at rates of 29% and 27%, respectively. After paediatric cardiac surgery AKI is also common, although the prevalence is highly variable among different investigations. The estimated incidence is somewhere between 15%-60%, although a recent single-centre study using the KDIGO-criteria presented an incidence of 9.3%. AKI in neonates and children, regardless of triggering event, significantly correlates with in-hospital mortality and prolonged hospital stays. The long-term consequences of renal failure have been described as hypertension, proteinuria and chronic kidney disease, which is alarming since chronic renal pathology in youth is known to have extensive adverse effects.

URINARY BIOMARKERS OF RENAL DAMAGE Current diagnosis and staging of AKI rely on changes in plasma creatinine concentration or urine output. However, using plasma creatinine as a biomarker for renal dysfunction in the paediatric population presents several challenges. In early life, plasma creatinine levels primarily reflect maternal levels and are expected to decrease during the initial postnatal week. A failure of creatinine levels to decrease might signify impaired renal function, which may not be identified using the KDIGO definition. Additionally, plasma creatinine is a delayed marker of kidney function and may not accurately reflect minor renal impairment. Blood sampling, a requirement for diagnosis, poses practical and ethical challenges in children. These impediments collectively contribute to the problems in defining the incidence of PO-AKI and developing successful clinical trials and interventions for paediatric AKI.

Novel urinary biomarkers initially identified in high-risk populations show promise in early and precise diagnosis of paediatric AKI, potentially surpassing plasma creatinine analysis. However, there remains a lack of studies validating their use. A recent consensus statement recommends employing a combination of damage and functional biomarkers, along with clinical information, to identify high-risk patient groups, enhance AKI diagnosis, optimize care processes, and aid AKI management. Nevertheless, the same consensus statement also acknowledges that substantial knowledge gaps persist, necessitating further research. One significant obstacle in using urinary biomarkers for AKI is the release of endogenous substances during inflammation, clouding the interpretation of biomarker concentration increases in immune-stimulated patients. However, these challenges may be less significant in PO-AKI as children generally have fewer comorbidities and thus less acute/ chronic inflammation. Additionally, the timing of potential renal insults (anaesthesia and surgery) is known and can be accounted for. Different biomarkers reflecting increased urinary concentrations indicate damage at various nephron levels. Thus, if properly evaluated urinary biomarkers may prove to be an accurate and useful predictor of PO-AKI and also give mechanistic insight into the cause of the renal injury.

RISK FACTORS OF PAEDIATRIC POSTOPERATIVE ACUTE KIDNEY INJURY Several risk factors contribute to paediatric PO-AKI beyond the inflammatory response induced by surgery per se. Events in the perioperative setting, such as hypotension, hypoxia, infections, mechanical ventilation, fluid shifts, blood loss and exposure to nephrotoxic medications, are potential culprits. Renal hypoperfusion due to hypotension may occur due to various reasons, including hypovolemia due to blood loss or dehydration after fasting and inflammation-induced capillary leak. In adults it has been demonstrated that intraoperative hypotension is associated with AKI in noncardiac surgical populations. Longer hypotensive periods and lower blood pressure results in higher AKI probabilities. Infants with vasopressor treatment or high fluid infusion rates during abdominal surgery have higher risk of AKI compared with those without blood pressure support. Another potential risk factor is the choice of anaesthetic. It was demonstrated that volatile anaesthesia, compared with total intravenous propofol anaesthesia, is associated with reduced urine output and higher incidence of PO-AKI in adults. Finally, it was recently described that female sex confers protection against AKI. This has not previously been examined in a paediatric population or in the perioperative setting.

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • Postoperative acute kidney injury
  • Pediatric kidney injury
  • Pediatric renal failure
  • Urinary biomarkers
  • Pediatric urinary biomarkers
  • Pediatric postoperative kidney injury
  • Pediatric anesthesia
  • Risk factors for pediatric acute kidney injury
04

Who can participate

Ages eligible
0 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospitalised paediatric patients undergoing major non-cardiac surgery in any of the specified investigator sites

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Elective, urgent or emergency in-patient major non-cardiac surgical procedures performed under general anaesthesia with or without regional analgesia with a planned procedure duration of at least 60 minutes.
  • Paediatric patients (0-16 years old)

Exclusion criteria

Exclusion Criteria:

  • Declined participation.
  • Ongoing renal replacement therapy
  • Acute Kidney Injury (according to KDIGO)
  • Known chronic kidney disease
  • Procedure involving surgery of the kidney
  • Procedures requiring clamping of blood flow to or from the kidney
  • Body weight \<2kg
  • Procedure involving contrast administration
  • Established rhabdomyolysis (CK-levels >1500 U/L)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Children undergoing major non-cardiac surgery under general anaesthesia

    Eligible participants are children aged 0-16 years admitted for non-ambulatory, non-cardiac major surgery requiring general anaesthesia with an estimated duration of at least 60 minutes, including elective, urgent, and emergency procedures. Non-ambulatory surgery is defined as a planned overnight hospital admission following the procedure.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative AKI

    Incidence of postoperative AKI, defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) creatinine criteria, based on changes in plasma/serum creatinine concentration from baseline within the postoperative period: * AKI Stage 1: Increase in plasma/serum creatinine ≥ 0.3 mg/dL (26.5 µmol/L) within 48 hours postoperatively OR 1.5-1.9 times baseline plasma/serum creatinine within 7 postoperative days. * AKI Stage 2: Increase in plasma/serum creatinine 2-2.9 times baseline p/s creatinine within 7 postoperative days. * AKI Stage 3: Increase in plasma/serum creatinine \> 3 times baseline plasma/serum creatinine within 7 postoperative days OR increase in plasma/serum creatinine to 4.0mg/dL (353.6 µmol/L) OR Initiation of renal replacement therapy OR decrease in eGFR to \< 35mL/min per 1.73 m2. All within 7 postoperative days. Baseline creatinine is defined as a plasma/serum creatinine value obtained within 24 hours prior of commencement of surgery.

    Time frame: Within 7 postoperative days

Secondary outcomes

  1. Agreement and association between changes in plasma/serum creatinine and urinary biomarkers of renal injury.

    Examples of urinary biomarkers: Neutrophil gelatinase-associated lipocalin (NGAL) Kidney injury molecule-1 (KIM-1) Tissue inhibitor of metalloproteinase 2 (TIMP-2) Insulin-like growth factor binding protein-7 (IGFBP-7) S100 calcium-binding protein A8 (S100A8) Osteoprotegerin (OPG) Galectin 3 Elastase Cystatin C Albumin/Creatinine-ratio

    Time frame: Within 7 postoperative days

  2. Time from surgery to first AKI-qualifying creatinine

    Time frame: Within 7 postoperative days

  3. Perioperative risk factors associated with postoperative AKI

    Time frame: Within 7 postoperative days

  4. Diagnostic accuracy of plasma cystatin C for postoperative AKI and agreement with creatinine-based definitions.

    These analyses aim to evaluate how well urinary biomarkers discriminate AKI versus no AKI within the postoperative window. Biomarker distributions will be assessed and skewed biomarkers will be log-transformed as appropriate. Defined rules for values below/above assay limits (LLOQ/ULOQ) will be applied (e.g., imputation at LLOQ/2 for below LLOQ, or use of censored methods if needed) based on approach specified per assay. If urine dilution adjustment is used (e.g., indexing to urine creatinine), both raw and indexed values will be examined and available in main text or in supplement. The primary diagnostic measure will be the area under the receiver operating characteristic curve (AUROC) with 95% CI (e.g., DeLong method). ROC curves will be presented for each biomarker. If clinically meaningful cut-offs are available, sensitivity, specificity, positive/negative predictive values, and likelihood ratios will be reported with 95% CIs. If no established cut-offs exist, an "optimal" cut-of

    Time frame: Within 7 postopertive days

  5. Associations between AKI and mortality, length of stay and renal replacement therapy

    Time frame: Within 7 postoperative days

Other outcomes

  1. Incidence of postoperative dysnatraemia and associated risk factors

    Time frame: Within 7 postoperative days

  2. Incidence of postoperative dyschloremia and associated risk factors.

    Time frame: Within 7 postoperative days

  3. Incidence of postoperative dyskalemia and associated risk factors.

    Time frame: Within 7 postoperative days

  4. Incidence of postoperative AKI defined by urine output

    Urine output criteria for AKI will be recorded where available, but creatinine-based KDIGO criteria constitute the primary diagnostic definition. If patient age at time of surgery ≥ 28 days: AKI Stage 1: \<0.5 mL/kg/h for 6-12h AKI Stage 2: \<0.5 mL/kg/h for ≥ 12h AKI Stage 3: \<0.3 mL/kg/h for ≥24h or anuria ≥12h If patient age at time of surgery \< 28 days: AKI Stage 1: \<1 mL/kg/h for ≥24h AKI Stage 2: \<0.5 mL/kg/h for ≥24h AKI Stage 3: \<0.3 mL/kg/h for ≥24h or anuria ≥12h

    Time frame: Within 3 postoperative days

  5. Incidence of perioperative oliguria and relation to postoperative AKI

    Time frame: Urine ouput during anaesthesia and in relation to AKI during the first 7 postopertaive days.

07

Study locations

6 of 16 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in publications from the POAKIDS study, including baseline characteristics, perioperative variables, outcome data, and biomarker measurements. All data will be fully anonymised at the individual level so that no participant can be identified.

Supporting information: Study protocol

Time frame: Data will be available beginning 12 months after publication of the primary results and will remain available upon reasonable request for at least 5 years thereafter.

Access criteria: Access to the de-identified dataset will be granted to qualified researchers upon reasonable request. Requests must include a brief description of the research question, analysis plan, and intended use of the data. All requests will be reviewed by the POAKIDS steering committee. Data will be shared only for scientifically sound projects and for purposes consistent with the original study objectives and ethical approvals. Data will be shared through secure data transfer following approval of a data sharing agreement. No direct identifiers or site-specific identifiers will be included in the shared dataset.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 33 months is above that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 20, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first sites in Canada, Croatia and Netherlands. 4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • Hospital das Clínicas HCFMUSP · São Paulo, BrazilNot yet recruiting→Recruiting
  • IRCCS Istituto Giannina Gaslini · Genova, ItalyNot yet recruiting→Recruiting
  • University Hospital of Belgrade · Belgrade, SerbiaNot yet recruiting→Recruiting
  • Sahlgrenska University Hospital · Gothenburg, SwedenNot yet recruiting→Recruiting
Show 3 added (1 Canada, 1 Croatia, 1 Netherlands)
  • Montreal Children's Hospital · Montreal, Canada
  • Children's Hospital Zagreb · Zagreb, Croatia
  • Radboud UMC · Nijmegen, Netherlands
Sep 29, 2026
Sponsor
Collaborators added: Lund University·University Childrens Hospital Belgrade·Children's Hospital Zagreb·University Children's Hospital Basel·Montreal Children's Hospital of the MUHC·and 7 more
All 12

Lund University · University Childrens Hospital Belgrade · Children's Hospital Zagreb · University Children's Hospital Basel · Montreal Children's Hospital of the MUHC · McGill University Health Centre/Research Institute of the McGill University Health Centre · Insel Gruppe AG, University Hospital Bern · Radboud University Medical Center · Tel Aviv Medical Center · Tel Aviv University · University of Geneva, Switzerland · Sahlgrenska University Hospital

Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    3 sites added — first sites in Canada, Croatia and Netherlands. 4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Hospital das Clínicas HCFMUSP · São Paulo, BrazilNot yet recruiting→Recruiting
    • IRCCS Istituto Giannina Gaslini · Genova, ItalyNot yet recruiting→Recruiting
    • University Hospital of Belgrade · Belgrade, SerbiaNot yet recruiting→Recruiting
    • Sahlgrenska University Hospital · Gothenburg, SwedenNot yet recruiting→Recruiting
    Show 3 added (1 Canada, 1 Croatia, 1 Netherlands)
    • Montreal Children's Hospital · Montreal, Canada
    • Children's Hospital Zagreb · Zagreb, Croatia
    • Radboud UMC · Nijmegen, Netherlands
    Sponsor Collaborators added: Lund University·University Childrens Hospital Belgrade·Children's Hospital Zagreb·University Children's Hospital Basel·Montreal Children's Hospital of the MUHC·and 7 more
    All 12

    Lund University · University Childrens Hospital Belgrade · Children's Hospital Zagreb · University Children's Hospital Basel · Montreal Children's Hospital of the MUHC · McGill University Health Centre/Research Institute of the McGill University Health Centre · Insel Gruppe AG, University Hospital Bern · Radboud University Medical Center · Tel Aviv Medical Center · Tel Aviv University · University of Geneva, Switzerland · Sahlgrenska University Hospital

    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07351149
Lead sponsor
Uppsala University
Collaborators
Uppsala University Hospital, Karolinska Institutet, Skane University Hospital, Karolinska University Hospital, Istituto Giannina Gaslini, Queen Silvia Children's Hospital, Gothenburg, Sweden, Feculdade de Medicina da Universidade de Sao Paulo - Brasil, University of Belgrade, University Hospital, Basel, Switzerland, Hospices Civils de Lyon, University of Bern, University Hospital, Geneva, Child and Adolescent Health Service - Perth, Lund University, University Childrens Hospital Belgrade, Children's Hospital Zagreb, University Children's Hospital Basel, Montreal Children's Hospital of the MUHC, McGill University Health Centre/Research Institute of the McGill University Health Centre, Insel Gruppe AG, University Hospital Bern, Radboud University Medical Center, Tel Aviv Medical Center, Tel Aviv University, University of Geneva, Switzerland, Sahlgrenska University Hospital
Responsible party
Robert Frithiof (Professor, Uppsala University) — Principal investigator
First posted
Jan 20, 2026
Start date
Mar 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Robert Frithiof, Md, PhD
Contact
robert.frithiof@uu.se
+46-72-2406252
Arash Emami, MD
Contact
arash.emami@uu.se
Robert Frithiof, MD, PhD
principal investigator · Uppsala University Hospital, Uppsala, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion